NEW YORK (GenomeWeb News) – Biobase today said that it has inked an agreement with the University of Southern California and the Children's Hospital of Philadelphia to exclusively market and distribute their Annovar genomic annotation tool.
The software enables annotation of genomic variants on a variety of specieds including humans, said Beverly, Mass.-based Biobase. It rapidly screens and annotates genetic variants detected with next-generation sequencing platforms on a genome-wide level.
Biobase said that it would sell Annovar as a standalone product and as a complement to its own Genome Trax database of diseases, phenotypes, and functional effects of genomic variants assembled from published results.
"By integrating the annotation functionality of Annovar with the wealth of annotation databases provided by Biobase, users could be getting a boost on their ability to mine functional information from genome variants and accelerate biomedical discoveries," Kai Wang, the developer of Annovar and an assistant professor at the University of Southern California, said in a statement.
Terms of the agreement were not disclosed.